94results about How to "Reduce neurotoxicity" patented technology

Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and / or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.

The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.

The present invention relates to benzenesulfonyl piperazine compounds represented by a formula I or benzoyl piperazine compounds represented by a formula II, or pharmaceutically acceptable salts, solvates, stereoisomers or precursor drugs thereof, wherein various symbols are described in an instruction. The present invention further relates to preparation methods for the compounds, uses of the compounds in preparation of drugs for treatment and / or prevention of tumors and / or cancers, methods for treatment and / or prevention of tumors and / or cancers by using the compounds, and drug compositions containing the compounds having an effective treatment and / or prevention amount. The compounds of the present invention have characteristics of effective anticancer activity and low toxicity.

The invention relates to the field of virology and tumor therapy and particularly provides a recombinant HSV (herpes simplex virus). The recombinant HSV is capable of specifically duplicating and killing tumor cells in tumor cells by a high level but duplicating in normal cells by a low level, so that the recombinant HSV is not only high in tumor cell lethality but also remarkably reduced in sideeffect (especially neurotoxicity). Further, the invention relates to a viral vector constructed on the basis of the recombinant herpes simplex virus, a pharmaceutical composition containing the recombinant herpes simplex virus or the viral vector and application of the recombinant herpes simplex virus or the viral vector. The recombinant herpes simplex virus can be used for infecting and killing the tumor cells and delivering gene medicines into the tumor cells to realize gene therapy.

The invention provides a polypeptide polymer nanomaterial and a preparing method and application thereof. The polypeptide polymer nanomaterial comprises chitosan, a polypeptide sequence for recognizing beta-amyloid protein and a polypeptide sequence for activating autophagy, and the polypeptide sequences are connected to the chitosan. A polypeptide polymer prepared through solid-phase synthesis and Michael addition has good biological compatibility and anti-A[beta] neurotoxicity, polypeptide polymer nanospheres obtained from the polypeptide polymer can be co-assembled with A[beta] so as to effectively prevent aggregation of A[beta] and reduce the neurotoxicity of A[beta], meanwhile, a co-assembly can activate autophagy after entering cells, A[beta] can be degraded through autophagy, so that Alzheimer's disease can be treated in a synergic mode, the Alzheimer's disease treatment efficiency of the polypeptide nanomaterial is improved greatly, and application prospects are broad.

The present invention discloses one attenuated vaccinia virus Tiantan plant carrier and its preparation process and application, and the attenuated vaccinia virus is high attenuated TT.WHU.ZCI, CCTCC: V200417. The preparation process includes the following steps: A. constituting shuttle plasmid containing flanking sequence homogenous with the coding region sequence or coding region lateral sequences of the vaccinia virus Tiantan plant HA gene, or containing flanking sequence homogenous with the promoter sequence or lateral sequences of the vaccinia virus Tiantan plant HA gene; and B. homogenously recombining the shuttle plasmid and the vaccinia virus Tiantan plant to deactivate vaccinia virus HA gene part for high attenuating the vaccinia virus Tiantan plant. The attenuated vaccinia virus Tiantan plant carrier is used in preparing vaccine for treating or preventing infectious diseases.

The invention discloses new application of fucoxanthin to preparation of medicine for treating the alzheimer disease. The application is characterized in that fucoxanthin is used in the aspect of preparation of the medicine for treating the alzheimer disease, particularly in the aspect of preparation of medicine inhibiting acetylcholin esterase and the aspect of preparation of medicine inhibiting Abeta fibrosis. The application has the advantage that fucoxanthin has the inhibition function on acetylcholin esterase and Abeta fibrosis.

The invention provides a method of treatment of metastatic hormone-refractory prostate cancer involving substantially as concurrent administration of picoplatin and docetaxel. Prednisone may also be administered. Dosages and dosing regimens are provided.

The invention discloses a method for the large-scale production of neurotoxin in cobra venin and the reduction of the neurotoxicity, which comprises the following steps of: dissolving dry powder of cobra venin into Tris buffer solution of which the pH value is 7.5 and of which the concentration is 20 mmol / L, performing centrifugation and passing supernate through a 0.22 micrometer microfiltration membrane, putting samples on a CM Sepharose FF chromatographic column which is balanced with the solution; performing elution respectively by using balanced buffer solution containing sodium chloride to collect target albumen; removing the buffer solution by using a membrane bag of a 3K ultrafiltration membrane through ultrafiltration; adding a proper amount of hydrogen peroxide into desalinized albumen solution in proportion, after standing the mixture, degrading the hydrogen peroxide in the presence of a manganese dioxide catalyst, and performing filtration by using the 0.22 micrometer microfiltration membrane to remove the manganese dioxide so as to prepare finished products to be freeze-dried. Compared with the prior art, the method avoids adopting a purification step, improves the treatment capacity and yield, and is suitable for the large-scale production, and the neurotoxicity of the treated neurotoxin in the cobra venin is reduced greatly under the condition of invariable analgesic effect.

The present invention discloses one attenuated vaccinia virus Tiantan plant carrier and its preparation process and application, and the attenuated vaccinia virus is obviously attenuated TT.WHU.pZCI, CCTCC: V200416. The preparation process includes the following steps: A. constituting shuttle plasmid containing flanking sequence homogenous with the late promoter sequence or two flanking sequences of the vaccinia virus Tiantan plant HA gene; and B. homogenously recombining the shuttle plasmid and the vaccinia virus Tiantan plant to deactivate vaccinia virus HA gene part for obviously attenuating the vaccinia virus Tiantan plant. The attenuated vaccinia virus Tiantan plant carrier is used in preparing vaccine for treating or preventing infectious diseases.

The invention provides a novel stilbene derivative. The novel stilbene derivative is a compound with a general formula I or general formula II shown as the specification, or is an acceptable salt formed by the compound with the general formula I or general formula II and an inorganic acid or organic acid. Specifically, in the general formula I or general formula II, the atom represented by X is hydrogen atom or halogen atom, the substituent group represented by R is C1-C6 alkyl, 1-6 membered heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, substituent C3-C6 cycloalkyl, 3-6 membered heterocycloalkyl, substituent 3-6 membered heterocycloalkyl, 5-18 membered aryl, substituent 5-18 membered aryl, 5-18 membered heteroaryl, and substituent 5-18 membered heteroaryl. The novel stilbene derivative has neurogenesis activity and low nerve cell toxicity.

This invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumor activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumor medicines and medicines used in treatment of tumor diseases in combination of light or radiation therapy.

The invention provides a compound PAC-1 with an amorphous form, an oral medicinal composition containing the compound PAC-1 with an amorphous form, and a use of the compound PAC-1 with an amorphous form in the preparation of the oral medicinal composition. The PAC-1 with an amorphous form has obviously lower neurotoxicity than PAC-1 crystals, so the PAC-1 with an amorphous form is suitable for being used to develop medicines for treating tumors, especially metastatic tumors.

The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Abeta protein, including abeta1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode / disorder attributed to elevated levels of Abeta protein, including abeta1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders by administering an agent that either prevents production of Abeta, prevents aggregation of Abeta fibrils, or that increases the degradation or clearance of Abeta. In addition, the invention provides a method of treating or preventing a major or minor depressive disorder comprising administering an agent that prevents or interferes with Abeta-induced neurotoxicity. The present invention also relates to pharmaceutical compositions comprising such agents and methods of screening for novel agents.

Disclosed are a composition for reducing beta amyloid-induced neurotoxicity by inhibiting β-secretase activity, comprising a dibenzofuran derivative, and a method for preparing the same. Further disclosed is that the combination of the dibenzofuran derivative with a γ-secretase inhibitor or an anti-inflammatory agent shows higher activity with respect to reducing beta amyloid-induced neurotoxicity.